BeyondSpring Email Formats

Pharmaceutical Manufacturing • Manhattan, New York, United States • 51-100 Employees

BeyondSpring Email Formats

BeyondSpring uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@beyondspringpharma.com), used 61.1% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@beyondspringpharma.com	61.1%
{first name}.{last name}	john.doe@beyondspringpharma.com	22.2%
{first initial}{last name}	jdoe@beyondspringpharma.com	16.7%

Key Contacts at BeyondSpring

Shirley Liang

Director Of Finance And Investor Relations

Zhongkun Wang

Clinical Project Director

Hao Zhang

Assistant Director Of Cmc

June Lu

Sr. Director

Company overview

Headquarters	28 Liberty Street, New York, NY 10005, US
Phone number	+16463056387
Website	beyondspringpharma.com
NAICS	3254
SIC	283
Keywords	Oncology And Immuno-Oncology
Employees	51-100
Socials

About BeyondSpring

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.